A State-Of-The-Art Solution To The COVID-19 Pandemic

Pandemic Response Lab provides high-volume, low-cost testing and variant detection to communities across the U.S.

 

Now providing school “pool testing” for as low as $1 per child.

Contact Us

Going On Offense Against The Virus

By combining Opentrons’s advanced robotics technology with scientific innovation and best practices in infectious disease research, PRL provides fast and accurate testing for government agencies, hospitals, businesses, and schools. PRL is also conducting large-scale genome sequencing to track COVID-19 variants and identify potentially dangerous new mutations.

 

PRL is the only lab with the ability to do comprehensive testing, genome sequencing, and emerging strain characterization and prediction. Our capabilities and “pool testing” services will help reopen schools and businesses. Instead of playing catch-up, we are going on offense against the virus.

Surging Capacity To Meet National Demand

In September 2020, PRL opened its first lab in New York City, in partnership with the local   government. In March 2021, PRL opened its second lab in Washington, D.C. Additional labs are planned for Los Angeles, Seattle and other locales across the country. PRL conducts 30,000 to 50,000 PCR tests every day at its NYC lab, with capacity increasing to more than 500,000 tests this year as more labs open. PRL is also rapidly expanding its genome sequencing capacity and “pool testing” capabilities, and is on track to meet public health needs.

What We Do

PRL receives test samples from public and private hospitals, clinics, leading sample collection health companies, and other testing facilities. From there, automated assembly lines of robots conduct ‘gold standard’ RT-qPCR assay analyses on the samples. PRL also conducts whole and targeted genome sequencing on a subset of samples for surveillance testing. Results are quickly returned to testing facilities and public health authorities are immediately alerted to the presence of new variants and clusters.

Team Members

Jon BadalJon Badal with a mask

Jon Brennan-Badal

CEO

Jon is currently the CEO of Opentrons, a pioneer of affordable laboratory automation. Prior to his current role, he was the VP of Strategy at comiXology, a successful digital media company that was acquired by Amazon.

Chris Mahl

Executive Vice President and Chief Revenue Officer

Chris is currently the Executive Vice President and Chief Revenue Office of Opentrons Labworks Inc. Prior to his current role, Chris has helped companies like Salesforce.com, Oracle and Informatica navigate high growth stages to become established, customer-centric organizations and market leaders. Chris also serves as a Board of Directors Member at Omnichain Solutions and Advisor & Investor at 10 Ventures.

Raymond MillerRaymond Miller Masked

R. Miller

General Manager

R. Miller brings 40 years of experience in clinical diagnostics, having served in senior management positions at Quest Diagnostics, Northwell Health Systems, and Laboratory Corporation of America. Most recently, he served as Vice President and Managing Executive of the New York Metro Sub-Division for LabCorp’s Northeast Division.

CJ EnerCJ Ener with a mask

CJ Ener

COO

CJ is trained as a chemical engineer and brings a decade of experience in operations and process development from 3M Company, Target Corporate, and McKinsey & Company.

Haiping HaoHaiping Hao Masked

Dr. Haiping Hao

Lead Scientist

Dr. Hao has spent nearly 20 years running high-throughput genomic laboratories, serving as Associate Director at Johns Hopkins University Transcriptomics and Deep Sequencing Core.

Chiraag PatelChiraag Patel Masked

Dr. Chiraag Patel, MD

Medical Director

Dr. Patel brings experience as a medical director focused on molecular virology from P4 Diagnostix, as well as experience in diagnostics, vaccine research, and pathology from the Center for Medicare & Medicaid Services, FDA Office of Vaccine Research, and Stony Brook Medicine. Dr. Patel obtained his MBA from Columbia Business School.

Nili OstrovNili Ostrov Masked

Dr. Nili Ostrov, PhD

R&D Lead

Dr. Ostrov is a synthetic biologist with expertise in microbial genetics. Most recently in the lab of Dr. George Church at Harvard Medical School, she has extensive experience in developing methods for large-scale genetic engineering.

Peter Jung, MSc, MBA, C(ASCP)CM, MT-P(AAB)

Safety Officer

Peter has 20+ years working in commercial, reference, and hospital-based laboratories. He has worked as section manager and laboratory director for several hospitals in New York City – Bellevue, Brooklyn Hospital, and Lincoln Medical Center. He has extensive experience developing safety and emergency planning policies and procedures, including maintaining ongoing operations at Bellevue Hospital’s chemistry lab during Hurricane Sandy and assisting with emergency testing workflows for Zika at Lincoln Medical Center.

Paolo MitaPaolo Mita with a mask

Dr. Paolo Mita, PhD

Lead Scientist

Dr. Mita is a scientist focused on using cutting edge genomics techniques to study complex cellular behavior. After obtaining a joint Doctorate from the University of Milan and NYU Sackler School of Medicine, he co-developed the high-throughput analytical pipeline at the core of PRL’s diagnostic pipeline first at John-Hopkins University and then at NYU Langone Health.

Jon LaurentJon Laurent with a mask

Dr. Jon Laurent, PhD

R&D Director

Dr. Laurent brings nearly a decade of experience in high-throughput genetics experimentation from both the University of Texas at Austin and NYU Langone Health. He was instrumental in developing the highly-automated analytical genomics pipeline that is at the core of PRL’s COVID-19 diagnostic system.

Andrew MartinAndrew Martin with a mask

Andrew Martin, MS

Lead Automation Engineer

Andrew has nearly 20 years of experience managing high-throughput genetics cores, first at the University of Notre Dame, and then Scripps Research Institute, John Hopkins University, and most recently NYU Langone Health. He has intensive experience with a wide range of state-of-the-art laboratory automation technologies, and is responsible for millions of successful automated genotyping experiments on robotic systems he has orchestrated.

Henry LeeDr. Henry Lee with a mask

Dr. Henry Lee, PhD

Lead Scientist

Dr. Henry Lee is a biomedical engineer with expertise in systems and synthetic biology. He was previously a Research Associate with George Church at the Department of Genetics at Harvard Medical School and the Wyss Institute. He operates at the digital-to-bio interface, developing customized solutions for molecular technologies at scale.

Vai Hodel

Vaishali Hodel

Director of Laboratory Operations

Ms. Hodel is a veteran lab supervisor who most recently ran the Laboratory of Personalized Genomic Medicine of the Department of Pathology and Cell Biology at Columbia University.

Scientific Advisory Board

Jef BoekeJef Boeke

Jef Boeke

Scientific Advisory Board – Chair

Jef Boeke, Ph.D., elucidated a major form of DNA movement in the genome, whereby specific DNA regions called retrotransposons move via their RNA, and coined the term retrotransposition to describe the process. He has innovated extensively in tech/dev and biotech. He leads an international team synthesizing the highly engineered genome of the first synthetic eukaryote, Yeast 2.0. Since 2017, he has led the “Dark Matter Project,” which uses Big DNA tech to unravel the mechanisms by which genes get turned on and off. During the pandemic, research in his lab at NYU Langone Health led to the highly automated RT-PCR workflow and software technology licensed by NYU Langone to PRL, who then developed it to a clinically-approved testing platform. He has led several large multicomponent NIH, DARPA and NSF awards. In 2014, after 28 years at Johns Hopkins School of Medicine, he relocated to New York and founded the Institute for Systems Genetics at NYU Langone Health. Dr. Boeke is the chair of PRL’s Scientific Advisory Board and is a Member of the National Academy of Sciences, the American Academy of Arts & Sciences, and the American Academy of Microbiology.

Peter Palese

Peter Palese

Scientific Advisory Board

Peter Palese is a Professor of Microbiology and the Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. Dr. Palese’s research focuses on RNA-containing viruses, including influenza. He is a pioneer in reverse genetics for negative strand RNA viruses, crucial for the investigation of viral pathogenicity and development of novel vaccines. In recent years, Dr. Palese and his collaborators at Mount Sinai have focused on developing a Universal Influenza Virus Vaccine. Dr. Palese is a Member of the National Academy of Sciences, a Member of the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the National Academy of Inventors.

Orly Ardon

Orly Ardon

SCIENTIFIC ADVISORY BOARD

Orly Ardon, Ph.D., MBA, is the Science Manager for Digital Pathology Diagnostics at Memorial Sloan Kettering Cancer Center’s Pathology Department. Before that, she was heading the development of novel computer assisted diagnostic tools and the expansion of digital pathology collaborative initiatives at ARUP Laboratories in Salt Lake City, Utah. Orly combined her extensive scientific and business experience to identify and develop new machine learning based digital imaging and automation tools for state-of-the-art clinical operations and for improved patient care. Orly has BS, MS, and Ph.D. degrees in Microbiology from the Hebrew University of Jerusalem, and postdoctoral training in cell biology and virology at the University of Utah. She also has an Executive MBA from the University of Utah.

Michael Glickman

Michael Glickman

Scientific Advisory Board

Michael S. Glickman MD is a Member in the Immunology Program of the Sloan Kettering Institute, an Attending Physician in Infectious Diseases at Memorial Hospital, and an Alfred Sloan Chair at Memorial Sloan Kettering Cancer Center (MSK), where he directs the Center for Experimental Immuno-oncology. Dr. Glickman’s research focuses of the pathogenesis of mycobacterial infections and the interaction of microbes with cancer cells. Dr. Glickman is a graduate of Dartmouth College, an AOA graduate of Columbia University College of Physicians and Surgeons, completed internal medicine clinical training at the Massachusetts General Hospital of Harvard Medical School, and completed Infectious Diseases clinical training at the Albert Einstein College of Medicine/Montefiore Medical Center.

Chris Mason

Chris Mason

Scientific Advisory Board

Dr. Christopher Mason is an Associate Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction. The Mason laboratory develops new biochemical and computational methods to elucidate the genetic basis of human disease and create techniques in next-generation sequencing and algorithms for tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. Dr. Mason has won the NIH’s Transformative R01 Award and the NASA Group Achievement Award. He earned his Ph.D. in Genetics at Yale University and Post-doc in Clinical Genetics at Yale Medical School.

Leslie Mitchell

Leslie Mitchell

Scientific Advisory Board

Leslie Mitchell is co-founder of Neochromosome, Inc., a biotech startup whose chromosome synthesis and engineering technologies are changing the world of synthetic biology. Leslie has worked extensively on chromosome and genome engineering in both yeast and mammalian systems and helped lead the international Synthetic Yeast Genome Project, Sc2.0, aiming to build a designer yeast genome from scratch. Leslie completed her Ph.D. at the University of Ottawa and a postdoc that started at Johns Hopkins University School of Medicine and ended at New York University Langone Health.

Rahul Satija

Rahul Satija

Scientific Advisory Board

Rahul Satija, PhD, is a Core Faculty Member at the New York Genome Center (NYGC), with a joint appointment as Associate Professor at the Center for Genomics and Systems Biology at New York University (NYU). His lab develops experimental and computational methods to interpret the molecular contents of complex tissues and single cells. He received an NIH New Innovator Award in 2016, and in 2020 was selected to direct an NIH Center for Excellence in Genomic Science. Rahul holds a BS degree in Biology and Music from Duke University, and obtained his PhD in Statistics from Oxford University as a Rhodes Scholar.

Quick Facts

Fast Icon

Fast

Results in 24 hours or less

Chart Icon

Accurate
Up to 25% more sensitive than industry benchmark PCR tests

Target Icon

Affordable
Costs 50% less than the national average

PRL NYC Roadmap

Frequently Asked Questions

  • What COVID-19 analyses are you running at the lab?

    We run the “gold standard” RT-qPCR diagnostic test to detect SARS-CoV-2. We do not run analysis on antibody test samples.

  • Can I be tested for COVID-19 on-site?

    No. We do not collect samples directly from patients. We analyze samples collected from testing sites.
  • How long does it take to get results?

    Individual lab results are processed and delivered to testing facilities within 24 hours. “Pool testing” results are delivered in 12 hours or less.

  • Can I get my results directly from the lab?

    No. You receive your results from your testing facility.

  • How many tests can the lab run each day?

    PRL conducts 30,000 to 50,000 PCR tests every day at its NYC lab, with capacity increasing to more than 500,000 tests this year as more labs open around the country.

  • What certifications does the lab have?

    The lab has received federal CLIA certification and New York State CLEP approval.

  • What testing sites use the lab?

    A national network of public and private hospitals, clinics, and other diagnostic facilities use the PRL to analyze samples.

  • I need a COVID-19 test. Where do I go?

    Information on testing facilities can be found here.

  • Who runs the lab? Who owns it?

    PRL is run by a team of experts in genetics, clinical diagnostics, and robotics. PRL’s state-of-the-art labs use knowledge and technology licensed from NYU Langone based on research led by world-class geneticist Dr. Jef Boeke. PRL is a subsidiary of Opentrons Labworks Inc., a leading diagnostic life sciences company based in Brooklyn, NY.

     

  • Who is paying for the lab results?

    Testing facilities.

  • I work for a hospital or other testing facility interested in learning more, what should I do?

    Email [email protected] to talk to a specialist.

  • How is PRL helping schools to reopen?

    PRL is providing school “pool testing” for only $1 per child for lab servicing cost, helping ensure widespread availability of the service. “Pool testing” can help schools determine if COVID-19 is present in their community and then follow up to identify any positive individuals and conduct rapid contact tracing and mitigation steps. PRL’s advanced genome sequencing can also tell a school exactly which variant is present, a critical piece of information in shaping the community’s response.